Insights On Pharma Logistics

1. What Makes A Successful CGT Channel Strategy? Key Considerations For CGT Developers 11/5/2026

   Distribution model, customer network, and order submission are interlocking choices for cell and gene therapies, shaped by handling demands, treatment setting, and patient population.

2. Commercial Readiness: The ROI Of Defragmented Supply Chains 10/28/2026

   Clinical-stage supply chains often hide costs that emerge at commercial scale. Standardizing systems, documentation, and providers can reduce variability and improve long-term performance.

3. Extended Manufacturability: Why Cryopreservation Is A Commercial Enabler 10/28/2026

   Cryopreserved starting materials separate collection from manufacturing, improving capacity planning, enabling broader geographic reach, and redefining commercial readiness for cell therapies.

4. Building a Global Manufacturing Network: "Dual-Sourcing" Commercial Strategies 10/19/2026

   EU entry after FDA approval puts launch timing and supply continuity at risk. QP release, importation pathways, and distributed manufacturing networks all shape whether a biologic reaches the market predictably.

5. Integrated Services That Pass Inspections 10/1/2026

   Standardized supply chain workflows reduce risk, protect biological integrity, and enable compliant scaling from clinical trials through commercialization.

6. Ultra Low Temperature Packaging Solutions 9/3/2026

   Maintaining product integrity is critical for ultra-low temperature therapies. Learn key lessons from a complex gene therapy launch.

7. Global Complexity Demands Local Resilience 8/31/2026

   With integrated capabilities spanning early development through commercial manufacturing, our U.S. network helps customers build greater supply chain resilience, navigate uncertainty, and create a more reliable path to market.

8. 3 Decision Domains Shaping Sterile Drug Product Success 8/28/2026

   In sterile development, the decisions with the greatest downstream consequences are rarely recognized as such when they are made. Examine how these choices shape program outcomes across the lifecycle.

9. Clinical Trial Logistics: What Biopharma Needs To Prepare For Next 8/17/2026

   Fragmented clinical trial logistics are slowing programs and increasing risk. Learn how coordinated planning and digital visibility are becoming competitive advantages in complex, global studies.

10. Accelerating Drug Development Through Integrated CDMO And CRO Partnership 8/12/2026

    Coordinating drug substance, analytics, and clinical ops across multiple vendors puts you in the integrator role. See how connected CDMO-CRO partnerships eliminate that burden and reduce downstream risk.